microphoton x
microphoton x is a biophotonic company founded in 2022 that develops a cutting-edge optical technology platform combining Optical Tweezer, Raman Spectroscopy, and AI for rapid phenotypic antibiotic susceptibility testing. Their flagship product, the Biospex Analyser 3.0, enables susceptibility results within 30-60 minutes, simultaneous bacterial identification, and analysis directly from primary samples, addressing the global challenge of multidrug resistant bacteria. The company targets biomedical and diagnostic markets, aiming to revolutionize in vitro diagnostics with non-destructive single-cell chemical analysis. Their technology is validated by customer research and offers a unique advantage by detecting bacterial susceptibility before cell growth is affected, positioning microphoton x as a leader in fast, precise infection diagnostics.
microphoton x
microphoton x is a biophotonic company founded in 2022 that develops a cutting-edge optical technology platform combining Optical Tweezer, Raman Spectroscopy, and AI for rapid phenotypic antibiotic susceptibility testing. Their flagship product, the Biospex Analyser 3.0, enables susceptibility results within 30-60 minutes, simultaneous bacterial identification, and analysis directly from primary samples, addressing the global challenge of multidrug resistant bacteria. The company targets biomedical and diagnostic markets, aiming to revolutionize in vitro diagnostics with non-destructive single-cell chemical analysis. Their technology is validated by customer research and offers a unique advantage by detecting bacterial susceptibility before cell growth is affected, positioning microphoton x as a leader in fast, precise infection diagnostics.
TL;DR
Founded: 2021 (Oct 2021 listed)
HQ: Tutzing / Munich area, Germany
Product: Biospex Analyser (Raman spectroscopy + optical trapping platform)
Use case: Rapid phenotypic antibiotic susceptibility testing (30-60 minutes) and bacterial ID from primary samples
Investors / grants: Acmaios (seed) and Bayern Innovativ Project (grant)
Company Overview
Problem Domain
In vitro diagnostics; rapid antimicrobial susceptibility testing and microbial identification to combat multidrug-resistant infections.
Founded
2021
Industry
Biotechnology
Funding Track Record
5500000
Seed investment reported Feb 7, 2022
570000
Grant awarded Jul 27, 2023
Investor Signal
“Acmaios; Bayern Innovativ Project”